A 股代码：688235 A 股简称：百济神州 公告编号：2023-038 港股代码：06160 港股简称：百济神州 美股代码：BGNE 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 本次股票上市类型为首发战略配售股份（限售期 24 月）；股票认购 方式为网下，上市股数为 4,602,212 股。本公司确认，上市流通数量 等于该限售期的全部战略配售股份数量。 本次股票上市流通总数为 4,602,212 股。 本次股票上市流通日期为 2023 年 12 月 15 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2021 年 11 月 16 日出具的《关于 同意百济神州有限公司首次公开发行股票注册的批复》（证监许可 [2021]3568 号），同意百济神州有限公司（以下简称"公司"或"本公 司"）首次公开发行股票的注册申请。公司首次公开发行人民币普通股 （A 股）115,055,260 股，并于 2021 年 12 月 15 日在上海证券交易所科 1 创板上市（以下简称"本次公开发行"）。 ...

中国国际金融股份有限公司、高盛（中国）证券有限责任公司 关于百济神州有限公司 二、本次上市流通的限售股形成后至今公司股本数量变化情况 首次公开发行战略配售限售股上市流通的核查意见 中国国际金融股份有限公司（以下简称"中金公司"）与高盛（中国）证券 有限责任公司（以下简称"高盛中国"，与"中金公司"合称"联席保荐机构"） 作为百济神州有限公司（以下简称"百济神州"或"公司"）首次公开发行人民币普 通股（A股）股票并在科创板上市的联席保荐机构，根据《证券发行上市保荐业 务管理办法》《上海证券交易所科创板股票上市规则》和《上海证券交易所上市 公司自律监管指引第11号——持续督导》等法律、行政法规、部门规章及业务规 则，对公司首次公开发行战略配售限售股上市流通的事项进行了认真、审慎的核 查，核查情况如下： 一、本次上市流通的限售股类型 本次申请上市流通的限售股为本次公开发行时公司联席保荐机构中金公司 和高盛（中国）的全资子公司跟投的战略配售限售股，锁定期为自公司人民币普 通股（A 股）股票上市之日起 24 个月，共涉及的限售股股东数量为 2 户，对应 股票数量为 4,602,212 股，占截至 2023 年 11 月 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年11月30日 狀態: 新提交 本月底法定/註冊股本總額： USD 1,000,000 第 1 頁 共 7 頁 v 1.0.2 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2023年12月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 06160 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 9,500,000,000 | USD | | 0.0001 USD | | | 950,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | | 0 | | 本月底結存 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 授出購股權及受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2023年11月30 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二名承授人授出可認購 合共2,536股美國存託股份的購股權並向一百八十三名承授人授出涉及合共62,806 股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的購股權 於2023年11月30日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二名 承授人可認購合共2,536股美國存託股份的購股權。 授出購股權詳情 授出日期： 2023年11月30日 承授人數目： 二名 已授出購股權涉及 的相關股份數目： 32,968 授出的代價： 零 購股權詳情如下： 購股權總數 （美國存託股份）: 2,536 因已授出購股權獲行 ...

FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2023年12月1日 | 第一章節 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 是 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市(註11) | | | | | | | 證券代號 (如於香港聯交所上市) | 06160 | 說明 | | | | | | | | | | 已發行股份佔 | 有關股份發行前的 | 上一個營業日 | 發行價較市值的折讓/ | | | | | | | | | 發行股份 | 每股發行價 | 股份數目 | 現有已發行股份數目 | 的每股收市價 | 溢價幅度(百分比) | (註6及7) | (註1及7) | | | | | 百分比 | (註5) | (註7) | (註4、6及7) | | | | | | | | | 於下列日期開始時的結存 ...

FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2023年11月30日 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市(註11) | 是 | | | 證券代號 (如於香港聯交所上市) | 06160 | 說明 | | | | | | | 發行股份 | (註6及7) | 股份數目 | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | 於下列日期開始時的結存(註2) | 2023年11月1日 | 1,238,236,702 | | | | | | | 1). 於股份獎勵計劃下發行股份 | 因根據股權計劃授出的受限制股份單位獲歸屬（本 ...

薪酬委員會章程 I. 一般成立目標聲明 BEIGENE, LTD. BeiGene, Ltd.（「本公司」）董事會（「董事會」）薪酬委員會（「薪酬委員會」）（代 表董事會）的成立目標是履行與本公司董事及高級管理人員的薪酬有關的董事會 職責，監督本公司的整體薪酬架構、政策和計劃，並負責根據適用規則及規例編 製一份報告供納入本公司有關其股東週年大會的代理聲明或10-K表的年度報告。 薪酬委員會的主要目標是制定及實施薪酬政策與計劃，確保吸引並留住主要管理 人員，動員管理層實現本公司的企業目標及策略，以及把管理層的利益與本公司 股東的長期利益掛鈎。 II. 組成 在薪酬委員會任職的人數應由董事會不時確定，但應由不少於兩名成員組 成，每名成員應滿足根據納斯達克股票市場規則5605(d)訂立的獨立性標準，但 受納斯達克股票市場規則中的任何適用例外情況規限。在釐定薪酬委員會的成員 時，董事會將會考慮成員是否符合資格作為1934年《證券交易法》（經修訂）（「交易 法」）內規則16b-3中界定的「非僱員董事」，以及作為1986年《國內稅收法》（經修 訂）第162(m)條界定的「外部董事」。 董事會應每年委任薪酬委員會成員，並可 ...

授出購股權詳情 購股權詳情如下： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 授出購股權及受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2023年11月13 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二名承授人授出可認購 合共1,869股美國存託股份的購股權並向一百五十三名承授人授出涉及合共42,384 股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的購股權 於2023年11月13日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二名 承授人可認購合共1,869股美國存託股份的購股權。 | 授出日期： | 2023年11月13日 | | --- | --- | | 承授人數目： | 二名 | | 已授出購股權涉及 的相關股份數目： | 24,297 | | 購股權總數 ...

Financial Performance - Total revenue for Q3 2023 reached RMB 5,624,008 thousand, representing a 111.5% increase year-over-year[4] - Total revenue for the first three quarters of 2023 reached RMB 12,875,236 thousand, a significant increase from RMB 6,868,770 thousand in the same period of 2022, representing an increase of approximately 87.5%[21] - Net profit attributable to shareholders for the year-to-date period was RMB -3,878,105 thousand, with a basic earnings per share of RMB 0.99 for Q3 2023[4][5] - The diluted earnings per share for Q3 2023 was RMB 0.96, reflecting the impact of non-cash gains from arbitration settlements[10] - The basic and diluted earnings per share for the first three quarters of 2023 were both RMB -2.85, an improvement from RMB -7.80 in the same period of 2022[22] - Net loss for the first three quarters of 2023 was RMB 3,878,105 thousand, an improvement compared to a net loss of RMB 10,433,648 thousand in the same period of 2022, reflecting a reduction of approximately 62.9%[21] Research and Development - Research and development expenses totaled RMB 3,295,174 thousand in Q3 2023, accounting for 58.59% of total revenue, a decrease of 54.32 percentage points compared to the previous year[5][10] - Research and development expenses for the first three quarters of 2023 totaled RMB 9,177,446 thousand, compared to RMB 8,017,379 thousand in 2022, marking an increase of approximately 14.5%[21] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of RMB -5,401,589 thousand for the year-to-date period[5] - Cash flow from operating activities for the first three quarters of 2023 was negative RMB 5,401,589 thousand, compared to negative RMB 6,458,895 thousand in the same period of 2022, showing an improvement of about 16.4%[23] - Cash inflow from operating activities totaled RMB 11,932,632 thousand in the first three quarters of 2023, compared to RMB 10,716,565 thousand in 2022, reflecting an increase of about 11.3%[23] - Cash and cash equivalents decreased from RMB 20,132,630 thousand at the end of 2022 to RMB 17,910,776 thousand[18] - Cash and cash equivalents at the end of the period decreased to $17,827,502 from $27,193,265 year-over-year[24] - Initial cash and cash equivalents balance was $20,111,301, down from $25,875,226 year-over-year[24] Assets and Liabilities - Total assets at the end of the reporting period were RMB 40,191,661 thousand, a decrease of 9.1% compared to the end of the previous year[5] - Total current assets decreased from RMB 36,173,906 thousand at the end of 2022 to RMB 29,591,210 thousand as of September 30, 2023[18] - Total assets decreased from RMB 44,224,173 thousand at the end of 2022 to RMB 40,191,661 thousand as of September 30, 2023[18] - The total liabilities decreased from RMB 13,893,114 thousand in 2022 to RMB 12,878,455 thousand in 2023, a reduction of about 7.3%[21] - The company's total equity attributable to shareholders at the end of the reporting period was RMB 27,313,206 thousand, down 9.9% from the previous year[5] - The total equity attributable to shareholders decreased from RMB 30,331,059 thousand in 2022 to RMB 27,313,206 thousand in 2023, a decline of approximately 10.0%[21] Shareholder Information - The total number of shares issued by the company is 1,376,270,732, with 91.64% of shares issued overseas[11] - Total number of common shareholders at the end of the reporting period was 40,908[12] - Amgen Inc. holds 246,269,426 shares, representing 17.89% of total shares[13] - Baker Brothers Life Sciences, L.P. holds 152,602,311 shares, representing 11.09% of total shares[13] Operational Efficiency - The company experienced a significant increase in product revenue and collaboration income, contributing to improved operational efficiency[9] Government Support - The company received government subsidies amounting to RMB 13,207 thousand during the reporting period[6] Industry Risks - The company emphasizes the high risks and uncertainties in the biopharmaceutical industry, affecting drug development and commercialization[16]

Financial Performance - Total revenue for Q3 2023 reached $781.3 million, a year-over-year increase of 101.6% from $387.6 million in Q3 2022[5] - Total revenue for the third quarter ended September 30, 2023, was $781.308 million, a significant increase from $387.628 million in the same period of 2022, representing a growth of 101.0%[6] - Product revenue for the third quarter was $398.229 million in the U.S., up 198.5% from $133.431 million year-over-year, driven by strong sales of proprietary products[6] - In China, total revenue reached $287.935 million, compared to $233.077 million in the same quarter of 2022, marking a growth of 23.6%[6] - Product revenue, net collaboration revenue for the nine months ended September 30, 2023, was $1.56 billion, compared to $915.6 million for the same period in 2022, marking an increase of 70%[18] - The company reported a net profit of $215.4 million for the third quarter of 2023, a turnaround from a net loss of $557.6 million in the same quarter of 2022[18] - Net profit for the third quarter was $21.54 million, a turnaround from a net loss of $55.76 million in the same quarter of 2022, attributed to reduced operating losses and non-operating income[8] - Basic and diluted earnings per share for the third quarter were $0.16 and $0.15, respectively, compared to a net loss per share of $0.41 in the same period last year[9] Product Development and Approvals - Global product revenue amounted to $595 million, reflecting a 70% year-over-year growth[3] - Global sales of Baiyueze® reached $357.7 million, a 130% increase compared to the same period last year, driven by ongoing global launches for multiple indications[3] - The company regained global rights for BaiZeAn®, which has been approved in the EU and is under regulatory review in 10 other markets[3] - BaiZeAn® received approval from the European Commission for use as a monotherapy in adult patients with unresectable, locally advanced, or metastatic ESCC who have previously received platinum-based chemotherapy[4] - The FDA has accepted a Biologics License Application (BLA) for BaiZeAn® for first-line treatment of unresectable, recurrent, locally advanced, or metastatic ESCC, with a decision expected by July 2024[4] - The company received positive opinions from the CHMP supporting Baiyueze® for treating adult patients with relapsed or refractory follicular lymphoma[3] - The company expects to receive FDA approval for a new indication for Baiyueze® in Q4 2023 based on the PFS efficacy results from the Phase 3 ALPINE trial for R/R CLL/SLL[12] - The company plans to submit a supplemental NDA for Baiyueze® in combination with obinutuzumab for R/R FL adult patients in March 2024, anticipating FDA approval[12] - The company will submit a new indication sBLA for first-line gastric cancer treatment in 2023 and for ESCC in Japan in H1 2024[12] - The company will present long-term follow-up data from the Phase 3 ALPINE trial comparing Baiyueze® to ibrutinib for R/R CLL/SLL at the ASH annual meeting in December 2023[13] Operational Efficiency and Strategy - The company is steadily improving operational leverage while controlling expense growth[3] - The company expects product revenue growth to continue to outpace operating expense growth, leading to sustained operational leverage[7] - The company is advancing its global growth strategy with a focus on enhancing its oncology product portfolio[3] - The company is focused on expanding its drug pipeline and enhancing drug accessibility and affordability for cancer patients globally[19] - Future growth strategies include advancing clinical activities and regulatory submissions for new drug candidates[20] Manufacturing and Capacity - The flagship manufacturing facility in New Jersey is nearing completion and is expected to be operational by summer 2024, with over 1 million square feet reserved for future expansion[15] - The company’s Guangzhou facility has reached a total capacity of 64,000 liters, with ADC production facilities nearing completion[15] - The company is actively working on building production facilities to increase manufacturing capacity and meet future demand[20] Financial Position - Cash, cash equivalents, and short-term investments totaled $3.2 billion as of September 30, 2023, down from $4.5 billion at the end of 2022[9] - The company’s financial summary shows total assets of $5,524,879 thousand as of September 30, 2023, down from $6,379,290 thousand at the end of 2022[17] - Total liabilities decreased to $1,761,645 thousand as of September 30, 2023, compared to $1,995,935 thousand at the end of 2022[17] - Shareholders' equity totaled $3,763,234 thousand as of September 30, 2023, down from $4,383,355 thousand at the end of 2022[17] Collaboration and Partnerships - The company reported a significant increase in deferred revenue related to its collaboration with Novartis, contributing to overall revenue growth[5] - The company terminated a collaboration agreement with Zymeworks for the development and commercialization of a dual-targeting HER2 antibody-drug conjugate in Asia (excluding Japan), Australia, and New Zealand[16] Research and Development Expenses - Research and development expenses for the third quarter of 2023 were $453.3 million, up from $426.4 million in the same quarter of 2022, reflecting a year-over-year increase of 6%[18] Intellectual Property - The management highlighted the importance of maintaining intellectual property protection for its drugs and technologies as a key factor for commercial success[20]